Absci uses generative AI to design novel biologics and antibodies for drug discovery, with applications in dermatology, oncology, and immunology.
Absci is a biotechnology company that leverages generative AI to accelerate the discovery and development of biologics—complex therapeutic proteins such as antibodies. The company's AI Drug Creation Platform integrates wet-lab experiments with machine learning in iterative six-week cycles, enabling rapid data generation, model training, and de novo design of biologics. This closed-loop system allows Absci to optimize multi-parametric characteristics of drug candidates, including efficacy, stability, and manufacturability. One of its notable achievements is the development of ABS-201, an antibody candidate for androgenetic alopecia that targets prolactin receptors to stimulate hair follicle regeneration. The platform has also enabled AI-driven target discovery through reverse immunology, identifying novel antibody-target pairs from immune responders. Absci collaborates with pharmaceutical, technology, and academic partners to advance both internal and co-developed programs toward clinical trials, aiming to reduce the time and cost traditionally associated with biologic drug development.
Integrations: Custom integrations with pharma R&D pipelines, Academic research consortia, Technology partners in AI and lab automation
Platforms: Web
View full Absci profile on Tools-Radar | Browse Healthcare tools | Alternatives to Absci
Tools-Radar is a free directory of 10,000+ AI tools — discover, compare, and choose the right AI software for your needs. Visit tools-radar.com